List of Vaccines Companies in California - 78

3T is an immunotherapy company developing next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases in broad patient populations. By leveraging the power of the immune system to recognize, target, and destroy cancer cells, 3T's technology is advancing the development of next-generation therapies that have the potential to be safer, more effective, and even curative for difficult-to-treat cancers.

Abcepta is a biotechnology company that specializes in developing primary antibodies and custom services for research and drug discovery.

Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients. Leveraging its Antibody-Cell Conjugation (ACC) technology, the company links tumor-targeting antibodies to its proprietary immune effector cells, such as gamma delta T cells and natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring powerful, accessible cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.

Aegis Life, Inc. is a biotechnology company founded in early 2020 with a mission to prevent and treat existing, emerging, and future contagions. Our nucleic acid delivery technology Fusogenix PLV stems from more than a decade of research and development in gene delivery. We actively leverage the Fusogenix PLV platform to accelerate the discovery, clinical development, and manufacture of vaccines and therapeutics for infectious diseases.

AIVITA Biomedical is an Irvine, CA based company focused on the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development. These proprietary capabilities enable us to turn therapeutic discovery into reality, developing revolutionary cell-based treatments and healthcare products for the patients who need them. AIVITA is developing treatments for cancer, vision loss, and is bringing next-generation skincare formulations to consumers through its commercial product offerings.

Amyris (Nasdaq: AMRS) is a science and technology leader in the research, development and production of sustainable ingredients for the Clean Health & Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Our ingredients are included in over 3,000 products from the world's top brands, reaching more than 200 million consumers. Amyris is proud to own three consumer brands - all built around its No Compromise® promise of clean ingredients: Biossance™ clean beauty skincare, Pipette™ clean baby skincare and Purecane™, a zero-calorie sweetener naturally derived from sugarcane. For more information, please visit www.amyris.com.

CenExel ACT is dedicated to performing medical clinical trials to find new patient therapies in unique areas, including Japanese-and Chinese-bridging studies. Our Phase I Clinical Pharmacology Unit is a 30,000 SF, state-of-the-art, 90 beds, clinical research center, and features: Private patient rooms and ward setting, State of the art entertainment 24-hour medical coverage, 7 days a week, On-site Surgery Suite (2 Procedure Rooms, 3 Recovery Beds), Emergency Room and Intensive Care Unit located close by In the clinical trials area, we ffer investigational therapies for indications such as Migraines, Insomnia, Chronic Pain, Osteoporosis, Hormone Replacement Therapy, Diabetes and much more. We offer new and existing therapies that manage conditions where other medical therapies may have failed. Each and every CenExel patients receive the highest quality medical care. We notify the patient's primary care physician of enrollment and ongoing status and provide a full report at the conclusion of each study. To learn more about working with us as a Sponsor or CRO for your clinical trial visit CenExel.com/ACT or call 714-774-7777.

Anivive is focused on reshaping pet healthcare by bringing together experts in software development, veterinary medicine, and clinical research to accelerate the development of novel therapeutics. Anivive. Smarter for pet health.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

Antigen Discovery, Inc. (formerly ImmPORT Therapeutics, Inc.) provides research services and products specializing in high throughput protein microarray technology that simplifies proteomic biomarker discovery and enables serological and immune profiling of whole proteomes.

Applied Bio Tech Institute is a biotechnology company that develops animal-free health and environmental products, including oral vaccines, animal-free protein products, natural sweetener, and feed enzymes.

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed Kostaive®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries).

ATUM is an industry-leading provider of life science tools and solutions. Founded as DNA2.0 in 2003, we were a pioneer in the application of machine learning to synthetic biology and currently hold multiple patents covering several technologies, including our first-to-market Leap-In Transposase® platform. Our integrated offerings include Gene Design & Synthesis, Protein Production, Cell Line Development, and Master Cell Banking — all powered by our Leap-In Transposase® and machine learning platform. This means a streamlined path from sequence to Master Cell Bank (MCB) with just a click, ensuring efficiency, regulatory compliance, and innovative solutions tailored to our clients' needs. ATUM is privately held and is headquartered in Newark, CA.

Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Headquartered in San Francisco, USA, and with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biologics and machine learning to boost protein production. The proprietary method is based on years of scientific research from the University of Helsinki, Finland. Our goal is to drive significant progress in biotechnology by providing turnkey solutions that streamline production, improve quality, and unlock new therapeutic possibilities. We're a team of brilliant minds, each an expert in their field, united by a shared mission to make a real impact in a novel area of biotechnology. We are a highly experienced, entrepreneurial minded team with an impressive scientific background, that lives and breathes a casual, committed, and positive culture and spirit.

Avid Bioservices (NASDAQ:CDMO), is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology, biopharmaceutical, and cell & gene therapy industries. With over 30 years of experience, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Avid Bioservices positions are accessible via the Avid Bio Careers page at https://avidbio.com/careers/.

Benchmark Research, an Avacare business, has a track record of safety and expertise, having conducted more than 1,000 trials since 1997 at clinics located in California, Louisiana and Texas. Benchmark's superior team of motivated and focused investigators offers clinical trials experience in a wide range of therapeutic areas. Our knowledgeable investigators enthusiastically embrace clinical research and the opportunities that new therapies bring to the marketplace and patients. Dedication and experience aside, our investigators are also highly trained in GCP and FDA regulations.

The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HBV infection. Bluejay has exclusively licensed global rights to advance several HBV programs, including a best-in-class anti-HBsAg monoclonal antibody.

CancerVAX is a drug development company focused on developing novel therapeutics in the oncology space. In partnership with the UCLA School of Medicine, we are progressing two programs: 1) Ewing sarcoma; 2) Universal cancer vaccine. CancerVAX is privately funded

Celestial Therapeutics is developing novel therapies based on innovative and groundbreaking science to treat, prevent and cure infectious diseases, rare diseases and cancers.

Centivax’s mission is to accelerate the world’s transition to a post-pathogen humanity.

CrystalGenomics is a commercial stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for global development in California, and it is publicly traded on the KOSDAQ exchange (083790). CrystalGenomics has a product on the market and is developing several novel drug candidates in different therapeutic areas. The marketed product is Acelex® (polmacoxib), a next generation NSAID for the treatment of signs and symptoms of osteoarthritis. The first clinical stage program is CG-745, an epigenetic agent applicable to various types of solid and liquid tumors and currently, phase 2 clinical trials are ongoing for pancreatic cancer and MDS. The second clinical stage program is CG-549, a novel class antibiotic for MRSA where its phase 2a skin infection study in the US had been completed with a positive outcome of 100% clinical cure rate. The Company's therapeutic candidates are discovered and developed through its proprietary discovery platform technology which utilizes the integrated technologies of the SPS™ (technology for structure determination), the SCP™ (technology for the generation of lead compounds) and the SDF™(technology used for lead optimization) technologies. By leveraging its capabilities and the know-how in novel drug discovery and development, CrystalGenomics will continue to strive in making significant contributions for improving human health. For more information, please visit: www.cgxinc.com or www.crystalgenomics.com.

CONTRACT PHARMA is the multi media information outlet dedicated to bio/pharma outsourcing. From drug development to manufacturing, we cover the latest developments, views and opinions from industry leaders in print and online. CONTRACT PHARMA offers advertising opportunities in our print magazine, Contract Pharma Direct weekly e newsletter and on contractpharma.com. We are the only worldwide print publication focused on Bio/Pharma contract services, delivering a total qualified circulation of 20,013. (VAC audit statement) On Sept. 26-27, 2024 CONTRACT PHARMA will host its 23rd Annual Contracting & Outsourcing Conference & Tabletop Exhibition. This event brings together speakers from the FDA, industry leaders, and expert analysts to discuss issues critical to success for Pharma & Biopharma outsourcing. The one-day Tabletop Exhibition of 160 top contract service providers provides great exposure to outsourcing decision makers. CONTRACT PHARMA's Corporate Capabilities and Contract Services Directory is the largest single source for company profiles and contract services. This standalone print issue showcases the services of Bio/Pharma contract service providers. The Contract Services Directory is also available online at www.contractpharma.com/csd. It's an indispensable guide for contract services in print and online. Every week, thousands of Bio/Pharma outsourcing professionals go to www.contractpharma.com to read current features, find archive stories, and get breaking news and online exclusives. We also e-mail CONTRACT PHARMA DIRECT, our weekly e-newsletter, to more than 20,000 people. CPDirect is filled with the latest news, our most recent articles, and links to our popular annual features and upcoming meetings. Free subscriptions are available on our website. Contact us for more information on how your company can get involved with Contract Pharma.

Cytonus is reinventing drug-discovery and drug-delivery by questioning the principled approaches of pharmacodynamics (physiological effects of drugs) that has failed patients since the start of medicine. With a revolutionary platform technology called the Cargocyte, we believe the days of flooding the body with medicines with a hope and prayer to effect disease is not only antiquated, it is scientifically flawed. With a combination of precision drug delivery and in-vivo drug production the Cargocyte platform enables science and medicines to new level of effectiveness without compromising safety for patients.

It all started 40 years ago, when we dedicated ourselves to finding scientific solutions using components from natural sources such as Quillaja and Yucca. Since then, Desert King has been leading the way in responsibly sourcing and reliably delivering saponin based products to the world. We are a company based in the United States, Chile, and Mexico. From these locations, we supply products to more than 1,000 customers worldwide, all of whom endorse the quality of our products. We maintain long-term relationships of trust with our customers, reaching more than 60 countries. Our high value-added products provide solutions to global needs in a variety of industries, such as health, human and animal nutrition, cosmetics, mining and agriculture. This includes our QS-21, which is globally accepted as the human vaccine adjuvant quality benchmark. As pioneers in Quillaja domestication with more than 15 years of experience, we have established plantations to meet the growing worldwide demand while safeguarding the integrity of the native forest. Additionally, Desert King actively contributes to the protection and recovery of Quillaja Saponaria forests through sustainable development and harvesting techniques.

DNARx is a company developing multiple therapeutics for major unmet medical needs, with demonstrated vaccine capabilities as well as protein expression. The company has been awarded a DARPA contract for up to $10.7 million to develop medical countermeasures against biological threats.

Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. Dynavax develops, and commercializes novel vaccines.

Eclipsebio develops first-in-class technologies, analyses, and platforms for the development of tomorrow’s RNA-based and RNA-targeting therapies. With our extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, we provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. We offer our solutions as end-to-end partnerships, including custom assay development, for biopharma and biotech companies and as a la carte services. Our areas of support include: - The optimization and characterization of RNA-based vaccines and therapeutics through our eMERGE platform - Multiomic characterization of small molecule and small oligonucleotide targets - Robust validation of on-target, and the identification of off-target, effects from small molecule and small oligonucleotide drugs - Deep profiling of RNA for groundbreaking discoveries in academic research Contact us today to discover how we can provide you with the insights needed for RNA success.

We are now at the dawn of the synthetic biology revolution, which will spawn new applications, markets, and business models, improving human lives in countless ways. This revolution will be driven by new technologies that enable DNA writing at speed and scale. To catalyze this revolution, Elegen is creating a suite of ground-breaking technologies to achieve DNA writing with unparalleled speed, cost, and quality. Elegen is unlocking the power to reprogram biology and create biologic solutions in order to solve some of humanity's greatest challenges. Founded and led by Dr. Matthew Hill and located in San Carlos, CA, Elegen is a stealth-mode company that is well capitalized by top life science investors, including Andreessen Horowitz, 8VC, and KdT. The company is advised and staffed by leading biotechnology scientists and entrepreneurs, including Dr. Marc Unger, inventor of the Nanoflex™ valve and former CSO of Fluidigm. Dr. Hill has a PhD from Stanford and a proven track record of advancing innovative technologies from invention to commercial success.

EnGen is an early-stage biotechnology company pioneering a new approach to preventing and treating influenza. We're developing an effective, easy-to-manufacture, shelf-stable universal flu vaccine that confers long-term immunity to all Type A influenza strains—including those which cause seasonal flu and influenza pandemics. Seasonal flu causes 250,000 to 500,000 deaths every year. The CDC and other experts have cautioned that we are extremely vulnerable to the catastrophic occurrence of a global flu pandemic—on a scale that could far exceed both COVID-19 and the Spanish flu of 1918. In its Global Influenza Strategy (2019–2030) report, the World Health Organization has declared the development of a universal flu vaccine as an urgent need—but the unique nature and genetic makeup of the influenza virus poses a challenge to researchers focused on influenza treatment and vaccination. To address these issues, EnGen Bio is developing universal vaccines for Type A flu prevention. Effective for vaccination in both the $6B human and $0.5B veterinary markets, our antibodies also demonstrate potential for therapeutic treatment of influenza, with an additional $2B prospective market. If successful, our efforts will eradicate flu pandemics and dramatically decrease the global burden of illness and disease caused by influenza.

Engimata has a platform adjuvant technology that improves vaccine efficiency, reduces antigen dose and enhances vaccine stability outside the cold supply chain. Engimata is currently developing a vaccine against COVID-19 using its platform technology. Engimata’s vaccine is cost-effective, easy to scale up, and simple to manufacture and distribute outside the cold supply chain. This increases vaccine accessibility and stability, ultimately saving cost, resources, and lives. Vaccine wastage in the supply chain due to temperature fluctuations is a major problem for current vaccines and costs the government and WHO billions of dollars every year. In order to combat COVID-19, it is crucial to overcome transportation barriers and distribute a vaccine across the world.

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.

EV Therapeutics is developing novel therapies to induce an anti-tumor immune response in advanced stage metastatic colorectal cancers. Our technology is based on our proprietary modified extracellular vesicles (mEVs) that significantly enhance tumor antigen-specific T cell infiltration into the tumor microenvironment and synergizes with current immune checkpoint blockade therapies. Mechanistically, our therapeutic platform activates tumor-specific T cell costimulation. Our extensive pre-clinical data show that treatment with mEVs significantly improves survival in late-stage disease models. Our findings potentially translate to a significant survival advantage for human colorectal cancer patients with advanced disease. Our modified extracellular vesicles-based therapy also controls the minimal residual disease that can prevent cancer recurrence functioning as a cancer vaccine. We are seeking out-licensing, co-development, and partnering opportunities.

ExcepGen is a venture-backed, early stage biotechnology company located in San Francisco. The company is focused on solving fundamental underlying problems in drug discovery and applying those solutions to create a new generation of therapeutics.

Flow Pharma uses Artificial Intelligence (AI) to select small peptides called neoantigens on the surface of cancer cells optimal for killer T-cell attack identified by gene sequencing a patient's cancer cells. These peptides can be synthesized, loaded into FlowPharma's FlowVax therapeutic cancer vaccine platform, and injected into the patient to expand killer T-cells which can recognize and kill cancer cells expressing those neoantigen peptides. Flow Pharma is creating patient-specific, neoantigen based, immuno oncology therapeutics initially focused on cervical cancer (orphan drug application for advanced, metastatic disease), breast cancer and malignant melanoma.

Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different versions of the vaccinia virus. Olvi-Vec, our lead product candidate is currently in a Phase 3 registrational clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Olvi-Vec is also being developed in Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer. We are dedicated to advancing a pipeline of next-generation oncolytic immunotherapies that deliver the full complement of tumor neo-antigens with the power to stimulate a personalized immune response for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Information about our investigational products and clinical trials can be found here. For more information, please visit https://genelux.com/ and follow us on Twitter @Genelux_Corp and Facebook @Genelux. Olvi-Vec is an investigational product candidate not yet approved by the US Food and Drug Administration.

Enabling users to establish #ownership & #control over their Biosamples & derived datasets as Non-fungible Tokens. We call them #BioNFTs 🧬.

Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.

HTD Biosystems is a contract research & development organization providing development of injectable products. Founded in 2001, our services focus on the rapid advancement of proteins, antibodies, peptides and biological drug candidates from the bench to the clinic. Our capabilities include: • Formulation & Lyophilization Development • GLP Manufacturing of Tox lots • Biophysical Characterization Our experience includes solutions for developing stable injectables for biologics, high concentration proteins, poorly soluble compounds and controlled release formulations, HTD Biosystem's drug delivery technologies include: • Liposomes • Vaccines • Nanoparticles • Nano Suspensions •Lyophilized Products HTD Biosystem's analytical technologies include: • Characterization of sub-visible particles and aggregates • Solid-state characterization • Protein conformation and stability HTD has over 160 clients globally, ranging from small to large pharmaceutical companies in the North & South America, Europe, Australia & Asia. HTD has successfully completed several pharma quality audits.

ICON works to accelerate the development of live-saving drugs and devices by providing a wide range of consulting, development, and commercialization services.

ImmunityBio (previously NantKwest (NASDAQ: NK)) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells. ImmunityBio is uniquely positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care. Natural Killer cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. Our “off-the-shelf” activated Natural Killer (NK) platform have the capacity to destroy cancer and virally infected cells from the body. The safety of our NK cells as well as their activity against a broad range of cancers have been tested in multiple phase 1 clinical trials in the United States, Canada and Europe. In addition to our NK cells capability to be administered in the outpatient setting as an “off-the-shelf” living drug, it serves as a universal cell-based therapy without need for individualized patient matching. Moreover, our NK cell based platform has been bioengineered to incorporate chimeric antigen receptors (CARs) and antibody receptors to further optimize targeting and potency in the therapeutic disease. Our targeted therapeutic areas include: (1) cancer, focusing on bulky hematological cancers and solid tumors as well as cancer stem cells, (2) infectious diseases, including viral, fungal and bacterial infections, and (3) inflammatory diseases, ranging from rare inherited diseases to more prevalent autoimmune disorders.

International Stem Cell Corporation (OTCBB:ISCO) develops a powerful new stem cell technology called “parthenogenesis” that promises to significantly advance the field of regenerative medicine by addressing the significant problem of immune-rejection. Parthenogenesis utilizes unfertilized human eggs to create “parthenogenetic” stem cells (hpSC) that can be “immune-matched” to millions of persons of differing sexes and racial backgrounds. A relatively small number of hpSC lines could provide sufficient immune-matched cells to cover large parts of the world’s population. ISCO plans to create a bank of these valuable hpSC lines (UniStemCell™) to serve all populations across the world. Human parthenogenetic stem cells have great therapeutic potential, yet do not require viable human embryos, thus avoiding ethical issues. ISCO’s scientists are focused on using hpSC to treat severe diseases of the eye, the nervous system and the liver where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells. ISCO advances and operates three businesses: Lifeline Cell Technology, Lifeline Skin Care and Universal Stem Cell Bank.

At InvivoGen, we strive to provide life scientists worldwide with innovative, high quality and reliable reagents. As specialists in cell culture engineering and innate immunity, we are passionate about designing, developing, and bringing to market new tools and services for cutting-edge research. At our three regional headquarters — in Toulouse (France), San Diego (USA) and Hong Kong (China) — and through our dedicated multilingual customer support staff, we can provide researchers around the globe with the reagents and product information that they need to make the scientific breakthroughs of tomorrow. InvivoGen is a privately held company founded by university researchers in 1977 in Toulouse, France. Since then, we have gradually expanded with the opening of InvivoGen San Diego, in 1997, and InvivoGen Hong Kong, in 2014. Our unparalleled skills in microbial fermentation enable us to produce a wide range of bioactive molecules, including ultra-pure antibiotics, novel mycoplasma treatments and the largest available collection of pattern recognition receptor agonists, from various micro-organisms. Over 25% of InvivoGen’s employees hold a PhD in biology or chemistry. Through specialized R&D teams, they work together seamlessly to design, produce and validate novel plasmids, cell lines, vaccine adjuvants and synthetic ligands for research in areas as diverse as gene therapy, molecular immunology and vaccination. Moreover, based on our first-hand knowledge of innate immune receptor signaling pathways, we have devised an ever-expanding collection of reporter cell lines, including cytokine reporter cells and knockout (KO) cell lines for high-priority innate immune targets. Scientists depend on InvivoGen for quality, consistency and reliability. Whatever research challenges you are facing, count on InvivoGen to provide you with the tools and solutions that you need.

InvVax was incorporated in January 2013. Located in sunny Southern California, it maintains a strong affiliation with the UCLA, where its technology was originally developed. InvVax has access to a wide network of leading investigators in diverse disciplines, including molecular virology, immunology, pharmacology, and clinical infectious diseases.

FUJIFILM Irvine Scientific is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. FUJIFILM Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company's consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 50 years FUJIFILM Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services.

JCVI researchers work on mammalian genomics, universal flu vaccines, autoimmune diseases, infectious disease, influenza, yellow fever, malaria, microbiology, and synthetic biology.

Khloris Biosciences is a private biotechnology company located in the San Francisco Bay Area. We are dedicated to revolutionizing medical treatment and prevention of cancer and other diseases by harnessing the unlimited immunotherapeutic potential of induced pluripotent stem cells (iPSCs) for drug discovery, vaccine and cell therapies.

List Labs specializes in the production of native toxins, recombinant proteins, bacterial fermentation, assay development, contract manufacturing, and biotherapeutics. List Labs produces C. difficile toxin A and toxin B, shiga toxins, cholera toxin, anthrax toxins (PA, LF, and EF), pertussis toxin, diphtheria toxin, CRM197, tetanus toxin, staphylococcal enterotoxin B, botulinum toxins as well as several types of lipopolysaccharides (LPS) or endotoxin for purchase by the research community.

Mana.bio is an AI based drug delivery startup, creating a platform for Lipid Nanoparticle (LNP) development for oligonucleotide therapies including mRNA-based therapeutics, vaccines and gene therapy.

MediCell Technologies (MCT) believes that stem cells can bring unique and exceptional value to health care.We forms Strategic Partnerships with industry and academia entities to facilitate and accelerate preclinical development of stem cell therapies. We are working to advance the field of stem cell applications. Progenitor Biologics®, LLC and AT Scientific, LLC are wholly owned subsidiaries of MediCell Technologies DefenAge® is a brand of Progenitor Biologics.

Meissa is a private biotech company focused on the advancement of vaccines for respiratory viruses. Meissa was founded on proprietary technologies employing reverse genetics for rational design of more effective live attenuated vaccines. The technology is exclusively licensed from Emory University and Children’s Healthcare of Atlanta. Dr. Moore, together with Dr. Roderick Tang, a vaccine biotech expert, co-founded Meissa. They are supported by a team with extensive experience in all aspects of vaccine development. Meissa is currently a resident company at the Johnson & Johnson Innovation – JLABS in South San Francisco.

Minerva specializes in quality investigations, product development, technology transfer and productivity improvements services for the cell and gene therapy, biotech and medical device industries, using advanced data, knowledge and risk management. Our team of interdisciplinary professionals supply us and our clients with cutting-edge knowledge while keeping our rates very competitive. Our team includes Quality Investigators, Engineers, Data Analysts, Information Scientists, and Biotechnology professionals. We also have a network of advisors in Quality Investigations, Life Sciences, Data Sciences, and Engineering. We tailor our services according to our client's location and budget needs: • Full-time Remote Work with On-Location Manager • Part-time Remote work with partial On-Location • Virtual Person-to-Person Advisory Services • Full-time On-Location • Other arrangements as needed Minerva uses process characterization and data structuring to help companies grow through continuous improvement and effective change management. Our data-driven and risk-based reports on product development and sustaining are fast, reliable, and compliant, and designed to facilitate your analysis and decision-making. We are best known for our agile implementation of databases and information management systems for tracking and visibility of medical device development, drug development and approval, methods development, sample testing, and operations sustaining. Let Minerva help your company achieve its development, operations and quality objectives through our services in Knowledge Management, Data Management, Risk Management, and Language Management.

MDS is a contract research organization that provides molecular diagnostics and toxicology services to pharmaceutical and research institutions.

NEUVOGEN is an immunoncology company applying a systems approach to develop therapeutic whole cell cancer vaccines to transform how cancer is treated. Our mission is to serve patients with cancer by developing transformative therapies to meaningfully extend their lives. NEUVOGEN’s vision is to revolutionize cancer treatment by harnessing the full power of a patient’s immune system to eliminate cancer from their body. We have taken a fundamentally different approach to solving cancer. Unlike other early-stage immunoncology companies, we try to solve for multiple issues arising from the complexity of cancer biology. Our approach to solving cancer is based on the concept that in order to fully address the complexity of solid tumor cancer biology, many targets and multiple biologic pathways need to be addressed simultaneously. NEUVOGEN is advancing a broad pipeline of therapeutic whole cell cancer vaccine candidates designed to activate the patient’s immune system to target and eliminate existing tumors and prevent future metastases. Our research programs focus on therapeutic cancer vaccines to treat a wide range of tumor types across numerous solid tumor indications.

Our mission is to develop effective and affordable preventive vaccines for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders. Using our universal vaccine platform for Alzheimer’s, our goal is to induce antibody titers high enough to penetrate the blood-brain barrier and prevent pathological plaques, fibrils, and oligomers to delay disease onset in cognitively unimpaired people at risk of Alzheimer’s.

Neutralizing Antibody Discovery

Polynoma LLC is a biotechnology company based out of 11230 Sorrento Valley Rd, San Diego, CA, United States.

PrimeVax Immuno-Oncology, Inc. is developing the only one-time, one-week cancer treatment. We use a combination of the dengue fever virus and autologous dendritic cells to induce a strong immune response along with personalized tumor targeting.

Primordial Genetics is a biotechnology company focused on improving the performance of bio-production systems, and enabling the development and improvement of microbes and enzymes used in pharmaceutical & industrial manufacturing and in agriculture. We develop and use whole-genome synthetic biology genetic tools to create efficient production organisms and industrial enzymes. Function Generator, the company’s flagship technology, enables rapid and flexible development of novel biological products and traits required for microbial production of amino acids, proteins, chemicals and other useful compounds. The technology is highly effective at overcoming ‘genetic black box’-type biological productivity or enzymatic activity bottlenecks that have resisted other attempts at improvement.

ProMab Biotechnologies, Inc is a revolutionizing biotechnology company that integrates cutting edge technologies to serve the global biomedical research community. We specialize in recombinant proteins, antibodies and engineered cell lines on which we are known to have built a superior reputation for quality and reliability. Our commitment to Excellence is exemplified by our newest service where we provide mRNA-LNP product and services that allows a swift and effective response to emerging infectious diseases. Join us in shaping the future of biotechnology and scientific progress. For more inquiries, visit our webiste: https://www.promab.com/. Email: info@promab.com

Redux Bio is an animal health product development company that creates, cultivates, and commercializes novel solutions to manage infectious disease.

Renovaro Biosciences, Inc. is a biotechnology company committed to developing advanced allogenic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as HIV and Hepatitis B virus (HBV) infection.

Replicate Bioscience is amplifying the power of RNA therapeutics by pioneering novel self-replicating RNA (srRNA) technology. Replicate’s off-the-shelf srRNAs contain two components: virally derived genetic code to drive controlled and self-limiting amplification, and the RNA encoding therapeutic proteins. Our library of viral vectors, selected for driving robust and sustained protein expression and orders-of-magnitude improved performance over linear mRNA, allow for the development of treatments in applications including oncology, infectious disease, and autoimmunity. Differentiated by a team of srRNA experts, a customizable library of synthetic srRNA vectors, and end-to-end development capabilities, Replicate is uniquely positioned to finally expand the reach of RNA treatments toward widespread use in infectious disease, immuno-oncology, autoimmune disease, and more.

Sepragen Corporation is based in Union City, California. We are passionate about making a positive difference in the lives of people by providing state of the art equipment used in the manufacture of life saving biological drugs and vaccines. Our products are used by industry leaders across four continents in the manufacturing of 24 FDA approved drugs and 100s of millions of doses of two well known Covid-19 vaccines, a capacity increase we enabled in 14 weeks! Sepragen's best in class equipment enable rapid scale up from lab to production scale often in existing small footprint facilities without impacting Capex and time to market. The growing suite of products include small footprint chromatography columns, innovative standard, single-use and continuous chromatography systems, buffer making systems, and cutting edge integrated Chromatography and buffer making systems as well as novel bioreactors. We are committed to bringing our customers products that deliver many times higher performance for the same investment in money, time and infrastructure all within the framework of quality, compliance and exceptional support. Our world class products are backed by an exceptional team of high performance and committed individuals- all focused on one thing: Delivering on what we promise! To learn more about Sepragen Corporation, please visit our website at <​https://www.sepragen.com>

Serimmune is an immune intelligence company that provides a holistic view of immunity to identify environmental factors in disease and health. Serimmune’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity.

Sorrento Therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

We lead the fields of transfusion and transplantation medicine by advancing science and technology. We provide hope for the future by teaching the medical leaders of tomorrow. We enhance lives by connecting donors to patients every day.

Styx, a pioneering biotech startup, is committed to transforming immunotherapy and cancer vaccine development by emphasizing enhanced immune memory for cancer treatment and prevention, particularly for challenging cancer types. The company's pipeline includes innovative CAR-T cell therapy product candidates targeting both solid and liquid tumors, as well as vaccine candidates addressing patient populations with high unmet medical need. With a mission to develop safer, more effective, and long-lasting immunotherapies and vaccines, Styx Biotechnologies is dedicated to improving global health outcomes and fostering a healthier future for all.

SutroVax is a biopharmaceutical company that focuses on delivering best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases, with a lead product candidate targeting invasive pneumococcal infections.

Telesis Bio is empowering researchers to accelerate the creation of novel synthetic biology solutions to address some of humanity's greatest challenges. With our breakthrough automation solutions for biological synthesis and expertise in DNA biology, we enable rapid, accurate, and reproducible writing of DNA and mRNA for wide-ranging biological applications. Around the world, innovators are leveraging Telesis Bio's technology to overcome current bottlenecks in synthetic biology workflows and advance the discovery of cutting-edge solutions for health and technology. We are proud of our growing collaborations with partners that include premier academic research institutions, emerging start-ups to nearly all of the Top 25 Biopharma companies. Telesis Bio is honored to play a part in several pioneering advances of our customers and collaborators ranging from novel infectious disease vaccines, precision immunotherapy for cancer and antibody therapeutics to creation of engineered meat substitutes and sustainable cellular agricultural products.

TeselaGen provides a revolutionary DNA design and assembly protocol generation service decoupling DNA design from any underlying assembly method, providing the most advanced Bio CAD/CAM system available. Taking full advantage of both in-house DNA constructs and the rapidly falling cost of de novo DNA synthesis, TeselaGen optimizes across a broad range of modern assembly techniques to produce fully scar-less DNA sequence assembly instructions ready for use at the bench or via automation. This approach releases the biologist from the major time, cost, and functionality limitations of traditional cloning to not only deliver the best overall assembly protocol, but to also create DNA constructs that may not be achievable by any other means. With TeselaGen's proprietary technology, these advances are now available for biologists at all levels of expertise who wish to assemble DNA simply, reliably, inexpensively, and with high fidelity.

Turnstone Biologics is a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to TIL therapy. Our innovative TIL therapy is based upon the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TILs, and is designed to overcome the limitations of first-generation bulk TILs that have demonstrated objective responses only in limited tumor types. Our most advanced program, TIDAL-01, is currently being evaluated in two Phase 1 studies in patients with melanoma, breast cancer, and colorectal cancer. We are also actively advancing a pipeline of preclinical programs, including TIDAL-02, our next Selected TIL program, and our TIDAL-01 and viral immunotherapy combination program.

Vault Pharma’s technology platform uses the human vault particle to deliver peptide payloads for unique immune signaling. We exploit the natural function of the human vault particle which is an immunological signal alert progenitor. Natural vault function is most notably characterized by vault particles being rapidly and robustly ingested by antigen presenting cells, APCs, specifically macrophages and dendritic cells. This favorable and natural property of vaults sets in motion an elegant and robust immune response that is non-inflammatory and results in many propitious effects including stimulation of antigen specific CD4 and CD8 T cells. Recombinant Vaults Allow for Novel Access To Immune Responses Recent data in multiple animal and cell models both published and unpublished demonstrate that vaults can and do produce an elegant, sophisticated and highly desired immune response characterized by unusually high and previous undescribed cellular immune responses (both CD4 and CD8) without inflammation, or cytokine storm. Evidence demonstrates that VPI-101 elicits an enhanced TIL response which recognize and kill cancer. Furthermore, animal studies demonstrate that VPI-101 vaults down regulate the tumor immune suppressive environment; reduced immune suppressive cells (reduce effective response) like T-regulatory cells (Tregs), myeloid derived suppressor cells (MDSC), IL-10 T cells, and induce systemic antitumor responses (stimulating splenic T-cell lytic activity against parental tumor cells). Recombinant vault particles are safe and non-immunogenic. Human vaults are identical in every person; therefore, they can be delivered as an off-the-shelf therapeutic. Vaults are highly stable, scalable, and homogenous in production

For two hundred years vaccines have been administered by intramuscular injection. Vaxart’s oral vaccine pills may change everything. Our vaccine pills act differently, by attacking invading pathogens in the places where they first enter the body: the mucosal areas, including the mouth, the nose and the gut. They are designed to trigger strong IgA and T-cell responses to repel and overwhelm the invading viral invaders. Vaxart has begun Phase II trials of its oral vaccine for Covid and for Norovirus– the only company in the world to reach this stage with a COVID-19 vaccine pill.

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-31, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease and VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Verndari was founded to advance global health by reinventing the vaccination process.Verndari, Inc. developed its patented VaxiPatch™, a complete vaccination kit that can be applied to the back of the wrist or arm. The kit contains a wipe to clean the vaccination site, the VaxiPatch™ device, and a spot bandage to cover the site post-vaccination. After vaccine administration, the VaxiPatch™ is simply peeled off the skin.The company is currently working to develop a vaccine candidate for COVID-19/

Vironexis is focused on transforming the future of cancer treatment by pioneering AAV-delivered T-cell immunotherapy. Our TransJoin™ AAV Gene Therapy Platform enables the creation of off-the-shelf, single-dose gene therapies designed to overcome the key challenges and shortcomings of current immunotherapies, including CAR-T and bispecific antibodies. Our current pipeline includes more than ten product candidates for blood-based cancers, solid tumor metastasis prevention, and a cancer vaccine. Our lead program, VNX-101, for the treatment of CD19+ acute lymphoblastic leukemia, is anticipated to begin clinical trials in the fourth quarter of 2024.

Wyatt Technology is a California-based developer and manufacturer of commercial light scattering instruments for sectors including medical and food and beverage.